LeMaitre Vascular Inc
$ 108.18
-4.85%
27 Feb - close price
- Market Cap 2,454,171,000 USD
- Current Price $ 108.18
- High / Low $ 112.74 / 105.85
- Stock P/E 46.63
- Book Value 17.33
- EPS 2.32
- Next Earning Report -
- Dividend Per Share $0.80
- Dividend Yield 0.7 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.16 %
- 52 Week High 115.33
- 52 Week Low 70.94
About
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Analyst Target Price
$109.22
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-07-30 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-27 | 2023-11-01 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 0.68 | 0.62 | 0.6 | 0.48 | 0.49 | 0.49 | 0.52 | 0.44 | 0.38 | 0.33 | 0.36 | 0.27 |
| Estimated EPS | 0.6625 | 0.57 | 0.5667 | 0.4978 | 0.49 | 0.44 | 0.47 | 0.39 | 0.36 | 0.3 | 0.32 | 0.25 |
| Surprise | 0.0175 | 0.05 | 0.0333 | -0.0178 | 0 | 0.05 | 0.05 | 0.05 | 0.02 | 0.03 | 0.04 | 0.02 |
| Surprise Percentage | 2.6415% | 8.7719% | 5.8761% | -3.5757% | 0% | 11.3636% | 10.6383% | 12.8205% | 5.5556% | 10% | 12.5% | 8% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Jan 1970 | Mar 2025 | Dec 2024 | Aug 2024 | May 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-26 | 2025-12-04 | 2025-09-04 | 2025-05-29 | None | 2025-03-27 | 2024-12-05 | 2024-08-29 | 2024-05-30 | 2024-03-28 |
| Amount | $0.25 | $0.2 | $0.2 | $0.2 | $0.2 | $0.2 | $0.16 | $0.16 | $0.16 | $0.16 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LMAT
2026-02-27 19:51:21
LeMaitre Vascular (Nasdaq: LMAT) announced that its management will participate in five investor conferences throughout March 2026. These engagements include presentations and one-on-one meetings at various healthcare-focused events such as the Leerink Partners Global Healthcare Conference and the Barclays Annual Global Healthcare Conference, both in Miami, and a virtual KeyBanc Capital Markets Healthcare Forum. The company specializes in devices and services for peripheral vascular disease.
2026-02-27 16:51:21
This article reports on a Form 144 SEC filing by Lemaitre Vascular Inc. (LMAT). The filing indicates a proposed sale of 8,464 shares of common stock with an aggregate market value of $962,272.00, acquired through a Restricted Stock Unit/Stock Option Exercise on December 2, 2023.
2026-02-27 14:50:00
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in five investor conferences throughout March 2026. Management will present at the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, and KeyBanc Capital Markets Healthcare Forum, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference and the 38th Annual ROTH Conference. The company specializes in devices and implants for peripheral vascular disease treatment.
2026-02-27 12:51:21
LeMaitre Vascular (LMAT) closed FY 2025 with strong Q4 revenues and EPS, reporting significant earnings growth and a net margin shift from 20.0% to 23.1%. While some narratives highlight new products and international expansion, others caution about the sustainability of margin expansion and valuation concerns given the P/E ratio and gap between current price and DCF fair value. The company's performance provides both bulls and bears with talking points regarding the drivers of its recent financial success.
2026-02-27 12:51:21
LeMaitre Vascular, Inc. reported strong Q4 2025 financial results, with sales growth of 16% and operating income growth of 47%, driven by strong performance in grafts, valvulotomes, and shunts across EMEA and APAC regions. The company provided optimistic 2026 guidance, projecting 12% sales growth and 21% adjusted operating income growth, and announced a new $100 million share repurchase program and a 25% dividend increase. Key strategic initiatives include continued international expansion of Artegraft, opening new direct sales channels in countries like Poland, and focusing on niche market acquisitions while maintaining profitability and cash flow.
2026-02-27 12:51:21
LeMaitre Vascular (LMAT) stock jumped 24.4% after reporting strong Q4 sales of $64.5 million, exceeding estimates, and increasing its quarterly dividend to $0.25. The company demonstrated consistent performance and healthy margins, with investors rewarding its profitability and stable growth. While valuation has expanded, its strong financial health and consistent execution suggest continued investor interest.
